We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Read MoreHide Full Article
Key Takeaways
TEM's Data and Services revenues rose 43.2% in Q1 2025, led by 58% growth in its Insights licensing business.
TEM signed a $200M licensing deal with AZN and Pathos, boosting its total remaining contract value.
Tempus deepened pharma ties with new data deals and a platform already adopted in oncology applications.
Tempus AI (TEM - Free Report) , a Chicago-based company focused on precision medicine, is building network effects via its three interconnected product lines. In the first quarter of 2025, revenues in its Data and Services segment increased 43.2% year over year to $61.9 million, driven by a 58% growth in Insights, the company’s data licensing business. Gross profit outpaced revenue growth, up 65.2% with only a modest 3% increase in the cost of revenues. The business has scaled significantly, securing deals with companies like Novartis, Merck EMD, Takeda and United Therapeutics over the past year. Against that backdrop, Tempus’ ability to sustain such strong growth rates in Data and Services is particularly impressive.
Most of these contracts span multiple years, with total remaining contract value reflecting data and services yet to be delivered. Several recent developments are setting the stage for the momentum to continue. A major highlight is Tempus AI’s $200 million data and modeling license agreement with AstraZeneca (AZN - Free Report) and Pathos to build the world’s largest foundation model, bringing AZN’s total remaining contract value to over $1 billion as of April 30. AZN and Pathos are also covering a large portion of the compute costs to train the model. Notably, the agreement’s non-exclusive nature allows Tempus to license data and build models with others in the future.
The company also expanded its collaboration with Illumina, which will use its multimodal data platform to accelerate clinical benefits of molecular profiling across all major diseases. In May, Tempus inked a large data agreement with Boehringer Ingelheim focused on biomarker development and novel discovery efforts, building on their past collaboration. Further, the company’s new oncology-focused platform, Loop, is already in use by a large pharmaceutical company to prioritize drug targets in patient subpopulations with severe unmet needs.
TEM’s Key Competitors in Data and Services
ICON (ICLR - Free Report) , an Ireland-based contract research organization, experienced a significant increase in overall biotech opportunities and a modest uptick in project win rates in the first quarter of 2025. However, it was ultimately offset by an increased number of customer-cancelled request for proposal (RFP) opportunities. In large pharma, RFP opportunities were softer in the quarter; still, ICLR’s high success rate underscored its strong positioning as a strategic partner.
IQVIA’s (IQV - Free Report) Technology & Analytics Solutions business continued the strong recovery trend in the first quarter of 2025, with clients launching new drugs and executing their commercial roadmaps. However, IQV faced slower decision-making from clinical customers on new programs, reflecting broader macroeconomic pressure and industry caution. IQVIA reported a 10% increase in average time from RFP issuance to award in the quarter, both year over year and sequentially.
TEM Outperforms Peers, Industry, But Valuation Stretched
Year to date, Tempus AI shares have surged 102.5%, outperforming the industry’s 18% growth and also delivering stronger returns than IQV and ICLR.
Image Source: Zacks Investment Research
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.47X compared to the industry average of 5.83X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
As you can see, earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture.
Image: Bigstock
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Key Takeaways
Tempus AI (TEM - Free Report) , a Chicago-based company focused on precision medicine, is building network effects via its three interconnected product lines. In the first quarter of 2025, revenues in its Data and Services segment increased 43.2% year over year to $61.9 million, driven by a 58% growth in Insights, the company’s data licensing business. Gross profit outpaced revenue growth, up 65.2% with only a modest 3% increase in the cost of revenues. The business has scaled significantly, securing deals with companies like Novartis, Merck EMD, Takeda and United Therapeutics over the past year. Against that backdrop, Tempus’ ability to sustain such strong growth rates in Data and Services is particularly impressive.
Most of these contracts span multiple years, with total remaining contract value reflecting data and services yet to be delivered. Several recent developments are setting the stage for the momentum to continue. A major highlight is Tempus AI’s $200 million data and modeling license agreement with AstraZeneca (AZN - Free Report) and Pathos to build the world’s largest foundation model, bringing AZN’s total remaining contract value to over $1 billion as of April 30. AZN and Pathos are also covering a large portion of the compute costs to train the model. Notably, the agreement’s non-exclusive nature allows Tempus to license data and build models with others in the future.
The company also expanded its collaboration with Illumina, which will use its multimodal data platform to accelerate clinical benefits of molecular profiling across all major diseases. In May, Tempus inked a large data agreement with Boehringer Ingelheim focused on biomarker development and novel discovery efforts, building on their past collaboration. Further, the company’s new oncology-focused platform, Loop, is already in use by a large pharmaceutical company to prioritize drug targets in patient subpopulations with severe unmet needs.
TEM’s Key Competitors in Data and Services
ICON (ICLR - Free Report) , an Ireland-based contract research organization, experienced a significant increase in overall biotech opportunities and a modest uptick in project win rates in the first quarter of 2025. However, it was ultimately offset by an increased number of customer-cancelled request for proposal (RFP) opportunities. In large pharma, RFP opportunities were softer in the quarter; still, ICLR’s high success rate underscored its strong positioning as a strategic partner.
IQVIA’s (IQV - Free Report) Technology & Analytics Solutions business continued the strong recovery trend in the first quarter of 2025, with clients launching new drugs and executing their commercial roadmaps. However, IQV faced slower decision-making from clinical customers on new programs, reflecting broader macroeconomic pressure and industry caution. IQVIA reported a 10% increase in average time from RFP issuance to award in the quarter, both year over year and sequentially.
TEM Outperforms Peers, Industry, But Valuation Stretched
Year to date, Tempus AI shares have surged 102.5%, outperforming the industry’s 18% growth and also delivering stronger returns than IQV and ICLR.
Image Source: Zacks Investment Research
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.47X compared to the industry average of 5.83X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
As you can see, earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.